Related Experiment Video
Updated: Dec 6, 2025

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Neoadjuvant chemotherapy in patients with invasive bladder cancer
David J Vaughn1, S Bruce Malkowicz
1Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania School of Medicine and the Abramson Cancer Center of the University of Pennsylvania, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104, USA.
Abstract:
Neoadjuvant chemotherapy has been extensively investigated in muscle-invasive bladder cancer. When taken together, the randomized controlled trials of neoadjuvant cisplatin-based combination chemotherapy demonstrate an improved survival over cystectomy alone. In addition, neoadjuvant chemotherapy can result in downstaging of primary tumors. As noted, a pT0 disease status at cystectomy is associated with a significant improvement in survival. A randomized controlled trial comparing neoadjuvant to adjuvant cisplatin-based chemotherapy shows that neither approach is superior. Finally, the ongoing EORTC/SWOG adjuvant chemotherapy trial, when completed, should add importantly to the literature concerning the role of systemic chemotherapy in muscle-invasive bladder cancer.
More Related Videos
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
08:43An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
Related Concept Videos
Urinary Tract Calculi VI: Surgical Management
Urinary Tract Calculi III: Medical Management
Urinary Tract Infection IV: Nursing Management
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists